All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Lymphoma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View lymphoma & CLL content recommended for you

#ASCO23

Share:

Jun 2, 2023

X post image

6 Jun 2023

CONGRESS| #ASCO23 @falchi_lorenzo @MSKCancerCenter presents longer term results of patients with DLBCL treated with epcoritamab+R-CHOP. The latest results support the preliminary data and this treatment induces high CMR rates with a manageable safety profile #lymsm

X post image

6 Jun 2023

CONGRESS| #ASCO23 Bei Hu @LevineCancer discusses efficacy and safety of patients ≥70 years with DLBCL who were enrolled in POLARIX trial and treated with Pola-R-CHP vs R-CHOP. Pola-R-CHP and R-CHOP had similar safety profiles but risk-benefit profile favored Pola-R-CHP #lymsm

X post image

6 Jun 2023

CONGRESS| #ASCO23 Andrew McDonald evaulates clinical trial assessing safety and efficacy of pembrolizumab in patients with R/R cHL and PMBCL. These data 9 months post analysis confirmed Q6W dosing in these patients had no new safety concerns with robust antitumor activity #lymsm

X post image

6 Jun 2023

CONGRESS| #ASCO23 Paul Harker-Murray @childrenswi summarizes CheckMate 744, a study evaluating salvage treatment with nivo + BV in children and adults with R/R cHL. Results demonstrate that most patients with low-risk R/R cHL can be salvaged with chemoimmunotherapy. #lymsm

X post image

6 Jun 2023

CONGRESS| #ASCO23 Nirav Shah @MedicalCollege reports on the updated results from the BRUIN study researching pirtobrutinib in patients with cBTKi pre-treated R/R MCL. Pirtobrutinib showed durable efficacy and a favorable safety profile. #lymsm

X post image

6 Jun 2023

CONGRESS| #ASCO23 Catherine Callaghan @UCIrvineHealth summarizes long-term safety data of pirtobrutinib in patients with R/R mantle cell lymphoma participating in the BRUIN trial. The data is consistent with previous findings regardless of follow-up time #lymsm

X post image

6 Jun 2023

CONGRESS| #ASCO23 @JenCrombie presents initial results of "SAVE: Safe Accelerated Venetoclax Escalation" investigating venetoclax with an accelerated dose ramp-up in patients with CLL. Currently, results show this treatment is feasible with low rates of TLS #lymsm

X post image

6 Jun 2023

CONGRESS| #ASCO23 Caron Jacobson @DanaFarber presents the real-world outcomes of patients receiving axi-cel for R/R FL. Results are consistent with patients observed in the ZUMA-5 trial #lymsm

X post image

6 Jun 2023

CONGRESS|#ASCO23 Steven Le Gouill @CHUnantes presents follow-up data from the LYMA trial evaluating efficacy and safety of rituximab maintenace post ASCT in patients with MCL. Ritiuximab was statistically superior in median EFS and PFS with no major toxicities reported #lymsm

X post image

6 Jun 2023

CONGRESS|#ASCO23 Swetha Kambhampati @cityofhope describes real-world outcomes of brexu-cel post BTK inhibitor, bendamustine, autoHCT and prior lines of therapy. Outcomes were consistent regardless of prior clinical characteristics #lymsm

X post image

6 Jun 2023

CONGRESS|#ASCO23 Reid Merryman @DanaFarber discusses the EPCORE NHL-2 trial evaluating epcoritamab with rituximab+lenalidomide in patients with R/R FL. This combination therapy showed potent antitumor activity and manageable safety profile #lymsm

X post image

6 Jun 2023

#ASCO23|Emanuele Zucca presents the LBA abstract on observation vs RT in pts with PMBCL achieving CMRs to standard immunochemotherapy. Data from the large IELSG37 trial supports the safe omission of mediastinal RT in pts with CMR after frontline immunochemotherapy
#lymsm

X post image

6 Jun 2023

CONGRESS|#ASCO23 |Ilseung Choi presents data from the phase II trial of CHOP + mogamulizumab in transplant-ineligible elderly pts with aggressive CCR4+ adult T-cell leukemia/lymphoma in Japan. Moga-CHOP-14 significantly improved PFS compared to historical control
#lymsm #lymphoma

X post image

6 Jun 2023

CONGRESS |#ASCO23| Qingqing Cai reports the primary results from JACKPOT8 phase II trial evaluating golidocitinib in R/R PTCL. The ORR was 44.3% with tumor responses observed across different subtypes. Golidocitinib demonstrated an acceptable safety profile #lymphoma #lymsm

X post image

6 Jun 2023

CONGRESS| #ASCO23 Anna Frustaci, Niguarda Cancer Center, presents results from MOLTO evaluating efficacy of atezolizumab, venetoclax & obinutuzumab in patients with untreated DLBCL-RS. Treatment was active in patients with DLBCL-RS and the study met it's primary endpoint #lymsm

X post image

6 Jun 2023

CONGRESS|#ASCO23 Tanya Siddiqi @cityofhope repots on the primary analysis of TRANSCEND CLL 004 investiating liso-cel in patients with R/R CLL/SLL. Results support the use of liso-cel in patients with R/R CLL/SLL with durable CR/Cri rate and high uMRD rates #lymsm #lymphoma

X post image

6 Jun 2023

CONGRESS| #ASCO23 Jennifer Woyach @OSUCCC_James discusses results from a trial evaluating IVO response-guided discontinuation vs IO indefinite treatment in CLL patients. Results so far show PFS is not superior for IVO vs IO but COVID-19 may have impacted this outcome #lymsm

X post image

5 Jun 2023

CONGRESS|#ASCO23 @Lymphoma_Doc @MDAndersonNews presents the global SUNMO trial currently enrolling patients to investigate safety and efficacy of mosunetuzumab+polatuzumab vedotin vs standard of care regimen in patients with R/R B-cell non-Hodgkin lymphoma #Lymsm

X post image

5 Jun 2023

#ASCO23 #lymsm https://t.co/Iim5Cfu5Qc

X post image

5 Jun 2023

How do these results impact clinical practice? Updated algorithm suggested by @Lymphoma_Doc #ASCO23 #lymsm

X post image

5 Jun 2023

#ASCO23 OS analysis from the ZUMA-7 trial presented by @Lymphoma_Doc
Axi-cel improves OS in 2L for refractory or early relapsed LBCL vs previous chemo-based regimen. #lymsm #CARTcells

X post image

4 Jun 2023

#ASCO23 | Further information on the safety data from the SWOG S1816 trial. #lymsm #ASCO2023

X post image

4 Jun 2023

#ASCO23 | Alex Herrera @cityofhope presents the LBA on the @SWOG S1826 trial, the largest NCTN study in HL. Nivo+AVD improves survival outcomes compared to BV+AVD in adolescents & adults with newly diagnosed advanced-stage classic #Hodgkin #lymphoma
#lymsm #ASCO2023

X post image

4 Jun 2023

RT @PallawiTorkaMD: With #ASCO23 around the corner, I am sharing my compilation of top #lymphoma #CLL abstracts this year that are potentia…

X post image

4 Jun 2023

CONGRESS|#ASCO23| Yesterday, Kerry Savage @BCCancer highlighted management challenges of treatment in patients with Peripheral T-cell lymphoma. Future trials should focus on both CHOP + drug ‘X’ and novel agent combinations to see the curative potential of novel agents #lymsm

X post image

1 Jun 2023

📢 1 day to go!

The @lymphomahub will be attending the 2023 @ASCO Annual Meeting on June 2–6.

Follow us to keep up to date with live and post-congress insights in #lymphoma.

#ASCO23 #leusm #cancertreatment

X post image

31 May 2023

📢 2 days to go!

The Lymphoma Hub will be attending the 2023 ASCO Annual Meeting on June 2–6.

Follow us to keep up to date with live and post-congress insights in #lymphoma.

#ASCO23 #leusm

#ASCO23

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ASCO 2023 American Society of Clinical Oncology

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Your opinion matters

When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?

Newsletter

Subscribe to get the best content delivered to your inbox